Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors: Yu-Hao Zhou, Xiu-Qiang Ma, Cheng Wu, Jian Lu, Shan-Shan Zhang, Jia Guo, Shun-Quan Wu, Xiao-Fei Ye, Jin-Fang Xu, Jia He

DOI: 10.1371/journal.pone.0039062

Abstract Summary

This meta-analysis of anti-obesity drugs found that orlistat improved multiple cardiovascular risk factors including cholesterol, blood pressure, and fasting glucose, while also reducing weight. Rimonabant showed benefits for weight loss and blood pressure reduction. Sibutramine only demonstrated weight loss and triglyceride reduction, suggesting limited cardiovascular benefits.

Why Brain? 🧠

Meta-analysis shows anti-obesity drugs reduce weight and cardiovascular risk factors. Orlistat improves cholesterol, blood pressure, and glucose. Rimonabant lowers blood pressure. Sibutramine shows limited benefits.

The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.